Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)
This study is testing a special vaccine combined with immunotherapy to help the body's immune system fight aggressive brain and spinal cord tumors. Researchers want to see if this combination is safe and helps children and young adults with these serious conditions.
This study is for children and young adults between the ages of 4 and 25 who have been diagnosed with specific types of fast-growing brain or spinal cord tumors. Participants must also meet certain health requirements, such as having strong enough blood counts and no active infections.
Participants will receive a peptide vaccine designed to target cancer cells, along with an immunotherapy drug, a standard chemotherapy medication, and a tetanus booster shot. Doctors will closely monitor their health, safety, and response to the treatment throughout the study.
The study takes place at medical centers in St. Louis, Missouri; Durham, North Carolina; and Houston, Texas. Please note that this study is currently suspended, meaning it is temporarily not accepting new participants.
- 1Tests a vaccine and immunotherapy combination for specific brain and spinal cord tumors
- 2Open to patients between 4 and 25 years old who meet specific health guidelines
- 3The study is currently suspended and not enrolling new participants at this time
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.